ISCT Regional Meeting
Columbus, Ohio
April 4-5, 2008
Presentations
OPENING REMARKS
Lynn O’Donnell, PhD—James Cancer Hospital & Research Institute
Nancy Collins, PhD—University of Toledo Medical Center
SESSION 1-KEYNOTE
Lentiviral MGMT Therapeutic Delivery in Glioma Management---Slides not available
Stan Gerson, MD--Case Western Reserve University
SESSION 2 – GTPS & INSPECTIONS
Session 2a-Preparing for Unannounced Inspections: FDA, FACT, AABB
Dave Krugh, MT (ASCP) SBB, CLS, CLCP (NCA)--James Cancer Hospital & Research Institute
Session 2b-Preparing for FACT Inspection--Common Citations
Lizette Caballero, BS, MT (ASCP)—Florida Hospital Cancer Institute
Session 2c-AABB Cellular Therapy (CT) Standards & Accreditation
Lynn O’Donnell, PhD—James Cancer Hospital & Research Institute
SESSION 3 – MOBILIZATION & APHERESIS
Session 3a-Update on Stem Cell Mobilization for Patients and Donors--check back later for updates
Steve Devine, MD—Ohio State University
Session 3b-Collection: Opposing Methods for HPC Harvests
Sergio Torloni, MD—Mayo Clinic, Phoenix, AZ
SESSION 4 – BASIC CELL PROCESSING
Session 4a-Basic Cell Processing: Cryopreservation, CD34 Enrichment, RBC Depletion
Carolyn Keever-Taylor, PhD—Medical College of Wisconsin
Session 4b-RBC Depletion
Deborah L. Griffin, MSc—University of Pittsburgh
SESSION 5 - CHALLENGES IN LABELING & TRACKING
Session 5a-Challenges Associated with Labeling, Product Tracking and Product Tracebility
Session 5b-Labels: When Good Labels go Bad?
Session 5c-ISBT 128 For Cellular Therapy: More than Labeling
Session 5d-Challenges in Cell Product Labeling, Tracking & Traceabiliy
Leigh Sims Poston, BS, MT (ASCP)—James Cancer Hospital & Research Institute
Dave Krugh, MT(ASCP)SBB, CLS, CLCP(NCA)—James Cancer Hospital & Research Institute
SESSION 6 – WHEN THINGS GO WRONG-DEVIATIONS TO DISASTERS
Session 6 –When Things Go Wrong-Deviations to Disasters
Lizette Caballero, BS, MT (ASCP)—Florida Hospital Cancer Institute
SESSION 7 – FLOW CYTOMETRY
Session 7a-Flow Cytometric Applications for Immunotherapy of Cancer
Lawrence Lamb, Jr, PhD—UAB School of Medicine
Session 7b-Human Progenitor Cell Enumeration by Flow Cytometry Practical Considerations
Bruce Briggs, MS, SI, (ASCP)--OSU Medical Center
SESSION 8—ADVANCED CELL PROCESSING: PRODUCT IMPACT ON CLINICAL OUTCOMES
Session 8a-Influence of Graft Content on Outcomes in Autologous and Allogeneic Transplantation--check back later for updates
Steven Devine, MD—Ohio State university
Session 8b-Umbilical Cord Blood: An Alternative Allogeneic Stem Cell Source for Transplantation
Mary J. Laughlin, MD—Case Western Reserve University
SESSION 9 – VALIDATION & QUALIFICATION
Session 9a-Validation & Qualification
Carolyn Keever-Taylor, PhD—Medical College of Wisconsin
Session 9b-Validation & Qualification
Lynn O’Donnell, PhD—James Cancer hospital & Research Institute
SESSION 10 – RELEASE TESTING & PRODUCT RELEASE
Session 10-Release Testing & Product Release
Deborah L. Griffin, MSc—University of Pittsburgh
